Andrea Lobo, PhD, science writer —

People with negative responses to a tuberculin skin test a few years after being vaccinated against tuberculosis had a significant, 25% lower risk of developing amyotrophic lateral sclerosis (ALS) in their lifetime, according to a study in Norway. Because a positive reaction is linked to the recruitment of T…

People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not diverge in major ways from the trial’s rules — experienced a significant slowing in disease progression compared with a placebo, the treatment’s developer, NeuroSense Therapeutics, announced. This finding…

Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin testing the experimental therapy prosetin in people with amyotrophic lateral sclerosis (ALS). The first two parts of the PRO-101 trial (NCT05279755) involved healthy participants and showed that the…

A test that assesses the electrical activity associated with blinking may help speed the diagnosis of amyotrophic lateral sclerosis (ALS) and monitor disease progression in people with the condition, a study found. Findings showed that certain electrical waves can significantly distinguish people with ALS from healthy controls or…

A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center (VUMC) and will establish an ALS research center at the Nashville school. Véronique Belzil, PhD, whose work is focused on developing tailored treatments for people with ALS, also will serve…

The U.S. Food and Drug Administration (FDA) soon will meet with BrainStorm Cell Therapeutics to discuss the company’s plans for a confirmatory Phase 3b trial of NurOwn in people with amyotrophic lateral sclerosis (ALS). The expedited, face-to-face meeting is scheduled for Dec. 6, less than two months…

A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million) to seven research projects aimed at developing new tests, treatments, and devices for neurodegenerative diseases. “Our partnership with UK DRI allows us to identify and back the most promising translational…

Having higher blood levels of uric acid may prevent or delay the decline in cognitive function in people with amyotrophic lateral sclerosis (ALS), according to a new study from Italy. High levels of uric acid are also associated with reduced odds of frontotemporal dementia, a form of dementia especially…

NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is testing PrimeC in people with amyotrophic lateral sclerosis (ALS). News of trial findings being expected in December follows the dosing of a final patient in the randomized portion of…

People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable quality of life and low stress levels, according to a survey conducted across nine European countries. When asked about new drug development, participants most commonly prioritized treatments that slow…